Silica Nanoparticle Drug Conjugates With Enzyme-Sensitive Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nanotherapeutic delivery systems face challenges in achieving targeted drug delivery, controlled release, and minimizing off-target toxicities, with liposomes relying on passive EPR effect and polymer-based systems lacking targeting capabilities.
Innovation Solution
Development of silica-based nanoparticle drug conjugates (NDCs) with covalently attached drug molecules, utilizing enzyme-sensitive linkers for controlled release and targeting moieties for specific cell types, such as cancer cells, and incorporating imaging labels for precise localization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If liposomes and polymer-based systems are used for drug delivery, then drug payload capacity is improved, but targeting capability deteriorates
Solution Approach 1:
The patent divides the drug delivery system into two functional components: a nanoparticle core that provides passive targeting and accumulation via EPR effect, and separate targeting moieties (ligands) that are attached to the nanoparticle surface to provide active targeting capability. This segmentation allows the system to simultaneously achieve both high drug payload capacity and specific targeting function.
2Productivity
If passive EPR effect is used for drug delivery, then drug delivery to tumor sites is improved, but controlled release capability deteriorates
Solution Approach 1:
The patent introduces enzyme-sensitive linkers as intermediary components between the nanoparticle surface and the attached drug molecules or targeting moieties. These linkers act as mediators that remain stable during circulation and passive accumulation via EPR effect, but are specifically cleaved by overexpressed enzymes at the tumor site to trigger controlled drug release. This resolves the contradiction by enabling both efficient passive delivery and reliable controlled release.
3Quantity of substance
If larger nanoparticle size is used, then drug payload capacity is improved, but interstitial permeation deteriorates
Solution Approach 1:
The patent optimizes the nanoparticle size parameter to a specific range (20-150 nm diameter) that balances two competing requirements: large enough to carry sufficient drug payload capacity, but small enough to achieve adequate interstitial permeation and penetration into tumor tissue. This parameter optimization resolves the contradiction by finding the optimal size window that satisfies both conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
NDCs provide controlled and predictable drug release, enhance biostability, and minimize off-target toxicities, demonstrating reduced receptor phosphorylation and effective drug delivery in cancer cells.
Implementation Method 1
the drug moiety and linker moiety form a cleavable (e.g., via a protease) linker-drug construct that is covalently linked to the nanoparticle
Data Source
AI summary
Described herein are nanoparticle drug conjugates (NDCs), which, in certain embodiments, comprise a non-toxic, multi-modality, clinically proven silica-based nanoparticle platform with covalently attached drug molecules/moieties. The nanoparticle drug conjugates (NDCs) demonstrate imaging capability and targeting ligands which efficiently clear through the kidneys. Furthermore, the conjugates incorporate therapeutic agents for cancer detection, prevention, and/or treatment.